Press Room

Navio Escola Sagres

Start
Tuesday, June 12, 2018 - 18:00
End
Tuesday, June 12, 2018 - 18:00
Location: Boston, United States
Cocktail dinner reception on board of the Portuguese Navy Tall Ship Sagres | Hovione

Cocktail dinner reception on board of the Portuguese Navy Tall Ship Sagres

By invitation only

 

Directions and Parking (Google Maps)

Further details will be forthcoming.

 

About Navio Escola Sagres
The Navio Escola Sagres is the Portuguese Navy's most commended sailing ship. Built in 1937 by the German yard Blohm & Voss this ship was one of four sister-ships ordered by the German Navy. After WWII, the Ship was conceded to the American Navy before substituting the previous "Sagres" in the Portuguese Navy in 1961. Being the Navy's biggest, this 89m (292ft) steel-built ship has two 42m (138ft) masts and a smaller Mizzen. It can fly up to 2000m2 (21527sqft) partitioned over 22 sails combining the traditional square sails, used in the 16th Century ships, in the forward masts and a gaff arrangement in the aft mizzen. It is now used as a school and training ship sailing around the World with a crew of 129 and 63 Navy Cadets.

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026